Background: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment.
Methods: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states.
Results: Preferences decreased with reduced treatment responsiveness and with increasing toxicity.
Conclusions: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.